<?xml version="1.0" encoding="UTF-8"?>
<p id="p0040">Many questions must yet be answered as coronavirus vaccines are developed. Research questions whose answers have immediate and practical application include these issues:
 <list list-type="simple" id="l0005">
  <list-item id="o0005">
   <label>•</label>
   <p id="p0045">Further resolution of case-fatality rates, viral reproductive number, and serosurveys that allow us to better appreciate the epidemiology of this infection</p>
  </list-item>
  <list-item id="o0010">
   <label>•</label>
   <p id="p0050">The identification and role of possible super-spreaders</p>
  </list-item>
  <list-item id="o0015">
   <label>•</label>
   <p id="p0055">Propensities for differential infection and transmission rates, as well as disease severity and fatality by age and ethnicity</p>
  </list-item>
  <list-item id="o0020">
   <label>•</label>
   <p id="p0060">Development of suitable animal models that closely mimic human pathophysiology and immunology must be identified and better optimized</p>
  </list-item>
  <list-item id="o0025">
   <label>•</label>
   <p id="p0065">Regulatory pathways for vaccine clinical trials and licensure in the absence of continuing outbreaks must be determined, as history demonstrates the intermittent and sudden appearance of outbreaks with these novel viruses—how might such regulatory pathways be altered in the event of a pandemic or more lethal mutations?</p>
  </list-item>
  <list-item id="o0030">
   <label>•</label>
   <p id="p0070">How shall issues of immunosensecence in the elderly and immunoimmaturity in infants and children be accounted for?</p>
  </list-item>
  <list-item id="o0035">
   <label>•</label>
   <p id="p0075">Why have we not seen widespread or lethal infections in children compared to adults?</p>
  </list-item>
  <list-item id="o0040">
   <label>•</label>
   <p id="p0080">What about special populations such as health care providers, pregnant women, immunocompromised individuals, and those with and without prior experience with various types of coronavirus infection?</p>
  </list-item>
  <list-item id="o0045">
   <label>•</label>
   <p id="p0085">How will such vaccines be equitably distributed—particularly in low income countries?</p>
  </list-item>
  <list-item id="o0050">
   <label>•</label>
   <p id="p0090">Better data on viral pathogenesis and human immune responses</p>
  </list-item>
 </list>
</p>
